Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xeris Biopharma Holdings, Inc. filings document the company’s commercial biopharmaceutical operations, financial results and governance as a Nasdaq-listed issuer. Its Form 8-K reports furnish quarterly and annual operating results, business highlights, financial guidance and product-related updates for Recorlev®, Gvoke® and Keveyis®.
The filing record also includes disclosure of Recorlev patent litigation under the Hatch-Waxman Act, involving Orange Book-listed patents and ANDA-related challenges. Proxy materials cover board composition, executive compensation, equity awards, shareholder voting matters and governance practices, while current reports document board changes and compensatory arrangements.
Xeris Biopharma Holdings director Brady James Aloysius sold 10,834 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $5.5414 per share under a Rule 10b5-1 trading plan. Following the sale, he directly holds 89,166 shares. The sale price reflects multiple trades in a range from $5.29 to $5.63 per share.
Xeris Biopharma Holdings Inc: The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the class following an internal realignment. The filing states certain Vanguard subsidiaries will report disaggregated holdings after the January 12, 2026 realignment.
The cover identifies the issuer address and CUSIP and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing describes that Vanguard no longer is deemed to beneficially own securities held by the listed subsidiaries in reliance on SEC Release No. 34-39538.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire a total of 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share. These options were granted under the company’s 2018 Stock Option/Stock Issuance Plan and had fully vested based on prior service conditions. Following the transactions, he holds 1,777,725 common shares directly and 25,000 shares indirectly through his spouse. The filing notes he disclaims beneficial ownership of some reported securities beyond his pecuniary interest.
Xeris Biopharma Holdings reported that officer Steven Pieper exercised stock options and acquired common shares. On March 5, 2026, he converted options into 27,891 common shares at $4.09 per share and 14,036 common shares at $5.93 per share through derivative exercises.
These options were originally granted on January 31, 2018 and December 10, 2020 under company stock option plans with vesting tied to continued employment. Following the transactions, he directly owned up to 1,408,940 common shares.
Xeris Biopharma Holdings, Inc. reported that company officer Beth Hecht executed two open-market sales of its common stock under a pre-established Rule 10b5-1 trading plan. She sold a total of 16,667 shares on March 2, 2026, at prices including $6.2401 and $7.06 per share, and held 1,226,507 shares afterward.
XERS filed a Form 144 reporting Rule 144 sales by Beth P. Hecht. The notice lists two 10b5-1 sales of 16,667 common shares each on 01/02/2026 and 02/02/2026, with gross proceeds of $123,775.48 and $124,147.15 respectively. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
Xeris Biopharma Holdings, Inc. files its annual report describing a commercial-stage biopharma business focused on chronic endocrine and neurological diseases in the United States. As of June 30, 2025, non‑affiliate common stock had an aggregate market value of about $731.1 million, and 172,431,290 shares were outstanding as of February 27, 2026.
The company markets three main products: Recorlev for Cushing’s syndrome, which it believes can reach about $1 billion in peak annual U.S. net revenue; Gvoke, a ready‑to‑use glucagon for severe hypoglycemia with an estimated $5.0 billion U.S. addressable market; and Keveyis for primary periodic paralysis with a U.S. market potential above $0.5 billion.
Xeris highlights its lead pipeline candidate XP‑8121, a once‑weekly subcutaneous levothyroxine using its proprietary XeriSol technology, targeting a hypothyroidism peak sales opportunity of $1.0 to $3.0 billion in the United States. The report also emphasizes the company’s XeriSol and XeriJect formulation platforms, extensive global patent estate, reliance on third‑party manufacturers, and detailed U.S. regulatory, intellectual property, and compliance frameworks governing its products and development programs.
Xeris Biopharma reported record results for the fourth quarter and full year 2025 and issued strong 2026 guidance. Fourth quarter total revenue rose to $85.8 million from $60.1 million, driven by Recorlev, Gvoke and Keveyis growth, and net income reached $11.1 million versus a prior-year net loss of $5.1 million.
For 2025, total revenue increased to $291.8 million from $203.1 million, with Recorlev sales more than doubling. The company generated full-year net income of $0.6 million, a sharp improvement from a $54.8 million loss in 2024. Adjusted EBITDA improved to $59.4 million from $1.2 million, reflecting higher sales and operating leverage.
For 2026, Xeris expects total revenue between $375 million and $390 million, implying more than 30% growth at the midpoint, and projects higher R&D and SG&A to support XP-8121 Phase 3 development and Recorlev investment while increasing Adjusted EBITDA versus 2025.